{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:34:51Z","timestamp":1790670891427,"version":"4.1.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T00:00:00Z","timestamp":1532563200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1038\/s41571-018-0074-3","type":"journal-article","created":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T09:35:19Z","timestamp":1532597719000},"page":"639-650","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":178,"title":["Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy"],"prefix":"10.1038","volume":"15","author":[{"given":"Luc","family":"Cabel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Proudhon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3161-7719","authenticated-orcid":false,"given":"Olivier","family":"Lantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Henri","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Pierga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5932-8949","authenticated-orcid":false,"given":"Fran\u00e7ois-Cl\u00e9ment","family":"Bidard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,26]]},"reference":[{"key":"74_CR1","doi-asserted-by":"crossref","first-page":"E5503","DOI":"10.1073\/pnas.1508736112","volume":"112","author":"K Sun","year":"2015","unstructured":"Sun, K. et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc. Natl Acad. Sci. USA 112, E5503\u2013E5512 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"74_CR2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cell.2015.11.050","volume":"164","author":"MW Snyder","year":"2016","unstructured":"Snyder, M. W., Kircher, M., Hill, A. J., Daza, R. M. & Shendure, J. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 164, 57\u201368 (2016).","journal-title":"Cell"},{"key":"74_CR3","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","volume":"14","author":"F Diehl","year":"2008","unstructured":"Diehl, F. et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med. 14, 985\u2013990 (2008).","journal-title":"Nat. Med."},{"key":"74_CR4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1097\/JTO.0000000000000263","volume":"9","author":"J-Y Douillard","year":"2014","unstructured":"Douillard, J.-Y. et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J. Thorac. Oncol. 9, 1345\u20131353 (2014).","journal-title":"J. Thorac. Oncol."},{"key":"74_CR5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1158\/2159-8290.CD-15-1483","volume":"6","author":"C Alix-Panabi\u00e8res","year":"2016","unstructured":"Alix-Panabi\u00e8res, C. & Pantel, K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 6, 479\u2013491 (2016).","journal-title":"Cancer Discov."},{"key":"74_CR6","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ejso.2017.01.010","volume":"43","author":"L Cabel","year":"2017","unstructured":"Cabel, L. et al. Circulating tumor cells and circulating tumor DNA: what surgical oncologists need to know? Eur. J. Surg. Oncol. 43, 949\u2013962 (2017).","journal-title":"Eur. J. Surg. Oncol."},{"key":"74_CR7","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","volume":"32","author":"LA Diaz","year":"2014","unstructured":"Diaz, L. A. & Bardelli, A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 32, 579\u2013586 (2014).","journal-title":"J. Clin. Oncol."},{"key":"74_CR8","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt, J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J.\u00a0Med. 376, 1015\u20131026 (2017).","journal-title":"N. Engl. J. Med."},{"key":"74_CR9","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N.\u00a0Engl. J. Med. 373, 1627\u20131639 (2015).","journal-title":"N. Engl. J. Med."},{"key":"74_CR10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409\u2013413 (2017).","journal-title":"Science"},{"key":"74_CR11","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803\u20131813 (2015).","journal-title":"N. Engl. J. Med."},{"key":"74_CR12","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Pembrolizumab versus ipilimumab in\u00a0advanced melanoma. N. Engl. J. Med. 372, 2521\u20132532 (2015).","journal-title":"N. Engl. J. Med."},{"key":"74_CR13","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AMM Eggermont","year":"2016","unstructured":"Eggermont, A. M. M. et al. Prolonged survival in stage\u00a0III melanoma with ipilimumab adjuvant therapy. N. Engl. J. Med. 375, 1845\u20131855 (2016).","journal-title":"N. Engl. J. Med."},{"key":"74_CR14","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber, J. et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med. 377, 1824\u20131835 (2017).","journal-title":"N. Engl. J. Med."},{"key":"74_CR15","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont, A. M. M. et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N.\u00a0Engl. J. Med. 378, 1789\u20131801 (2018).","journal-title":"N. Engl. J. Med."},{"key":"74_CR16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","volume":"13","author":"C Boutros","year":"2016","unstructured":"Boutros, C. et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat.\u00a0Rev. Clin. Oncol. 13, 473\u2013486 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"74_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-018-0964-4","author":"Y Meng","year":"2018","unstructured":"Meng, Y. et al. The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England. Eur. J. Health Econ. https:\/\/doi.org\/10.1007\/s10198-018-0964-4 (2018).","journal-title":"Eur. J. Health Econ."},{"key":"74_CR18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","volume":"545","author":"AC Huang","year":"2017","unstructured":"Huang, A. C. et al. T cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545, 60\u201365 (2017).","journal-title":"Nature"},{"key":"74_CR19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2386","author":"RW Joseph","year":"2018","unstructured":"Joseph, R. W. et al. Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2386 (2018).","journal-title":"Clin. Cancer Res."},{"key":"74_CR20","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/bjc.2015.467","volume":"114","author":"S Diem","year":"2016","unstructured":"Diem, S. et al. Serum lactate dehydrogenase as an\u00a0early marker for outcome in patients treated with\u00a0anti-PD-1 therapy in metastatic melanoma. Br.\u00a0J. Cancer 114, 256\u2013261 (2016).","journal-title":"Br. J. Cancer"},{"key":"74_CR21","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","volume":"4","author":"L Mezquita","year":"2018","unstructured":"Mezquita, L. et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol. 4, 351\u2013357 (2018).","journal-title":"JAMA Oncol."},{"key":"74_CR22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2016.05.031","volume":"65","author":"L Dercle","year":"2016","unstructured":"Dercle, L. et al. Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1\/-L1 therapy. Eur. J. Cancer 65, 33\u201342 (2016).","journal-title":"Eur. J. Cancer"},{"key":"74_CR23","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","volume":"5","author":"PC Tumeh","year":"2017","unstructured":"Tumeh, P. C. et al. Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol. Res. 5, 417\u2013424 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"74_CR24","doi-asserted-by":"crossref","first-page":"302ra133","DOI":"10.1126\/scitranslmed.aab0021","volume":"7","author":"I Garcia-Murillas","year":"2015","unstructured":"Garcia-Murillas, I. et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci.\u00a0Transl Med. 7, 302ra133 (2015).","journal-title":"Sci. Transl Med."},{"key":"74_CR25","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.15252\/emmm.201404913","volume":"7","author":"E Olsson","year":"2015","unstructured":"Olsson, E. et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol. Med. 7, 1034\u20131047 (2015).","journal-title":"EMBO Mol. Med."},{"key":"74_CR26","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","volume":"545","author":"C Abbosh","year":"2017","unstructured":"Abbosh, C. et al. Phylogenetic ctDNA analysis depicts\u00a0early-stage lung cancer evolution. Nature 545, 446\u2013451 (2017).","journal-title":"Nature"},{"key":"74_CR27","doi-asserted-by":"crossref","first-page":"346ra92","DOI":"10.1126\/scitranslmed.aaf6219","volume":"8","author":"J Tie","year":"2016","unstructured":"Tie, J. et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci. Transl Med. 8, 346ra92 (2016).","journal-title":"Sci. Transl Med."},{"issue":"Suppl. 15","key":"74_CR28","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1200\/JCO.2018.36.15_suppl.3565","volume":"36","author":"L Cabel","year":"2018","unstructured":"Cabel, L. et al. Prognostic impact of residual HPV ctDNA detection after chemoradiotherapy for anal canal carcinoma [abstract]. J. Clin. Oncol. 36 (Suppl.\u00a015), 3565 (2018).","journal-title":"J. Clin. Oncol."},{"key":"74_CR29","doi-asserted-by":"crossref","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda, C. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci.\u00a0Transl Med. 6, 224ra24 (2014).","journal-title":"Sci. Transl Med."},{"key":"74_CR30","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan2415","volume":"9","author":"J Phallen","year":"2017","unstructured":"Phallen, J. et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci. Transl Med. 9, eaan2415 (2017).","journal-title":"Sci. Transl Med."},{"key":"74_CR31","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","volume":"368","author":"S-J Dawson","year":"2013","unstructured":"Dawson, S.-J. et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368, 1199\u20131209 (2013).","journal-title":"N. Engl. J. Med."},{"key":"74_CR32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002199","volume":"13","author":"N P\u00e9cuchet","year":"2016","unstructured":"P\u00e9cuchet, N. et al. Base-position error rate analysis of\u00a0next-generation sequencing applied to circulating tumor DNA in non-small cell lung cancer: a prospective study. PLOS Med. 13, e1002199 (2016).","journal-title":"PLOS Med."},{"key":"74_CR33","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1158\/1078-0432.CCR-15-0321","volume":"22","author":"A Santiago-Walker","year":"2016","unstructured":"Santiago-Walker, A. et al. Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials. Clin. Cancer Res. 22, 567\u2013574 (2016).","journal-title":"Clin. Cancer Res."},{"key":"74_CR34","doi-asserted-by":"crossref","first-page":"42008","DOI":"10.18632\/oncotarget.5788","volume":"6","author":"ES Gray","year":"2015","unstructured":"Gray, E. S. et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget 6, 42008\u201342018 (2015).","journal-title":"Oncotarget"},{"key":"74_CR35","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1093\/annonc\/mdx212","volume":"28","author":"L Cabel","year":"2017","unstructured":"Cabel, L. et al. Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a\u00a0proof-of-concept study. Ann. Oncol. 28, 1996\u20132001 (2017).","journal-title":"Ann. Oncol."},{"key":"74_CR36","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","volume":"28","author":"JH Lee","year":"2017","unstructured":"Lee, J. H. et al. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann. Oncol. 28, 1130\u20131136 (2017).","journal-title":"Ann. Oncol."},{"key":"74_CR37","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1424675","volume":"7","author":"E Giroux Leprieur","year":"2018","unstructured":"Giroux Leprieur, E. et al. Circulating tumor DNA evaluated by next-generation sequencing is predictive\u00a0of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer. Oncoimmunology 7, e1424675 (2018).","journal-title":"Oncoimmunology"},{"key":"74_CR38","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","volume":"376","author":"DP Carbone","year":"2017","unstructured":"Carbone, D. P. et al. First-line nivolumab in stage IV or recurrent non\u2013small-cell lung cancer. N. Engl. J. Med. 376, 2415\u20132426 (2017).","journal-title":"N. Engl. J. Med."},{"key":"74_CR39","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney, G. T., Weiner, L. M. & Atkins, M. B. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 17, e542\u2013e551 (2016).","journal-title":"Lancet Oncol."},{"key":"74_CR40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35\u201344 (2016).","journal-title":"Cell"},{"key":"74_CR41","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124\u2013128 (2015).","journal-title":"Science"},{"key":"74_CR42","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189\u20132199 (2014).","journal-title":"N. Engl. J. Med."},{"key":"74_CR43","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Allen Van","year":"2015","unstructured":"Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207\u2013211 (2015).","journal-title":"Science"},{"key":"74_CR44","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers, Z. R. et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9, 34 (2017).","journal-title":"Genome Med."},{"key":"74_CR45","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-0261","volume":"7","author":"J Goodall","year":"2017","unstructured":"Goodall, J. et al. Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition. Cancer Discov. 7, 1006\u20131017 (2017).","journal-title":"Cancer Discov."},{"key":"74_CR46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188174","volume":"12","author":"F Koeppel","year":"2017","unstructured":"Koeppel, F. et al. Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. PLOS One 12, e0188174 (2017).","journal-title":"PLOS One"},{"key":"74_CR47","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1158\/1078-0432.CCR-15-2470","volume":"22","author":"C Jovelet","year":"2016","unstructured":"Jovelet, C. et al. Circulating cell-free tumor DNA analysis of 50 genes by next-generation sequencing in the prospective MOSCATO trial. Clin. Cancer Res. 22, 2960\u20132968 (2016).","journal-title":"Clin. Cancer Res."},{"key":"74_CR48","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/annonc\/mdu239","volume":"25","author":"L Mattos-Arruda De","year":"2014","unstructured":"De Mattos-Arruda, L. et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of\u00a0circulating cell-free tumor DNA: a proof-of-principle. Ann. Oncol. 25, 1729\u20131735 (2014).","journal-title":"Ann. Oncol."},{"key":"74_CR49","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","volume":"7","author":"AA Chaudhuri","year":"2017","unstructured":"Chaudhuri, A. A. et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 7, 1394\u20131403 (2017).","journal-title":"Cancer Discov."},{"key":"74_CR50","doi-asserted-by":"crossref","first-page":"e23028","DOI":"10.1200\/JCO.2017.35.15_suppl.e23028","volume":"35","author":"AA Davis","year":"2017","unstructured":"Davis, A. A. et al. Comparison of tumor mutational burden (TMB) across tumor tissue and circulating tumor DNA (ctDNA). J. Clin. Oncol. 35, e23028\u2013e23028 (2017).","journal-title":"J. Clin. Oncol."},{"key":"74_CR51","volume":"18","author":"N Yang","year":"2018","unstructured":"Yang, N. et al. The characteristics of ctDNA reveal the high complexity in matching the corresponding tumor tissues. BMC Cancer 18, 319 (2018).","journal-title":"BMC Cancer"},{"issue":"Suppl","key":"74_CR52","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.1158\/1538-7445.AM2018-5706","volume":"78","author":"D Fabrizio","year":"2018","unstructured":"Fabrizio, D., Lieber, D., Lipson, D. & Otto, G. A blood-based next-generation sequencing assay to determine tumor mutational burden (bTMB) is associated with benefit to an anti-PD-L1 inhibitor, atezolizumab [abstract]. Cancer Res. 78 (Suppl.), 5706 (2018).","journal-title":"Cancer Res."},{"key":"74_CR53","doi-asserted-by":"crossref","first-page":"11537","DOI":"10.1200\/JCO.2017.35.15_suppl.11537","volume":"35","author":"AA Davis","year":"2017","unstructured":"Davis, A. A. et al. Association of circulating tumor DNA (ctDNA) tumor mutational burden (TMB) with DNA repair mutations and response to anti-PD-1\/PD-L1 therapy in non-small cell lung cancer (NSCLC). J. Clin. Oncol. 35, 11537\u201311537 (2017).","journal-title":"J. Clin. Oncol."},{"key":"74_CR54","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.1158\/1078-0432.CCR-17-1439","volume":"23","author":"Y Khagi","year":"2017","unstructured":"Khagi, Y. et al. Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor-based immunotherapy. Clin. Cancer Res. 23, 5729\u20135736 (2017).","journal-title":"Clin. Cancer Res."},{"issue":"Suppl. 5","key":"74_CR55","first-page":"1295O","volume":"28","author":"DR Gandara","year":"2017","unstructured":"Gandara, D. R., Kowanetz, M. & Shames, D. S. Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy\u00a0in 2L+ NSCLC (POPLAR and OAK) [abstract]. Ann. Oncol. 28 (Suppl. 5), 1295O (2017).","journal-title":"Ann. Oncol."},{"key":"74_CR56","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","volume":"18","author":"S Turajlic","year":"2017","unstructured":"Turajlic, S. et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 18, 1009\u20131021 (2017).","journal-title":"Lancet Oncol."},{"key":"74_CR57","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/nm.4191","volume":"22","author":"RJ Hause","year":"2016","unstructured":"Hause, R. J., Pritchard, C. C., Shendure, J. & Salipante, S. J. Classification and characterization of\u00a0microsatellite instability across 18 cancer types. Nat. Med. 22, 1342\u20131350 (2016).","journal-title":"Nat. Med."},{"key":"74_CR58","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.critrevonc.2017.05.006","volume":"116","author":"E Ryan","year":"2017","unstructured":"Ryan, E., Sheahan, K., Creavin, B., Mohan, H. M. & Winter, D. C. The current value of determining the mismatch repair status of colorectal cancer: a rationale for routine testing. Crit. Rev. Oncol. Hematol. 116, 38\u201357 (2017).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"74_CR59","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1586\/14737159.2016.1156533","volume":"16","author":"N Buza","year":"2016","unstructured":"Buza, N., Ziai, J. & Hui, P. Mismatch repair deficiency testing in clinical practice. Expert Rev. Mol. Diagn. 16, 591\u2013604 (2016).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"74_CR60","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1158\/0008-5472.CAN-17-4060","volume":"78","author":"M-H Stern","year":"2018","unstructured":"Stern, M.-H. et al. Detecting MSI phenotype in circulating blood DNA. Cancer Res. 78, 4599 (2018).","journal-title":"Cancer Res."},{"key":"74_CR61","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky251","author":"I Ladas","year":"2018","unstructured":"Ladas, I. et al. Enhanced detection of microsatellite instability using pre-PCR elimination of wild-type DNA homo-polymers in tissue and liquid biopsies. Nucleic Acids Res. https:\/\/doi.org\/10.1093\/nar\/gky251 (2018).","journal-title":"Nucleic Acids Res."},{"key":"74_CR62","first-page":"3656","volume":"59","author":"P Srinivasan","year":"2018","unstructured":"Srinivasan, P., Tran, C., Stadler, Z. & Berger, M. F. Detecting MSI in plasma: implications for early detection of lynch associated tumors. AACR 59, 3656 (2018).","journal-title":"AACR"},{"key":"74_CR63","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J.\u00a0Med. 373, 23\u201334 (2015).","journal-title":"N. Engl. J. Med."},{"key":"74_CR64","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N.\u00a0Engl. J. Med. 373, 123\u2013135 (2015).","journal-title":"N. Engl. J. Med."},{"key":"74_CR65","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok, J. D. et al. Guidelines for the Evaluation of\u00a0Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. Clin. Cancer Res. 15, 7412\u20137420 (2009).","journal-title":"Clin. Cancer Res."},{"key":"74_CR66","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/annonc\/mdw531","volume":"28","author":"E Iwama","year":"2017","unstructured":"Iwama, E. et al. Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations. Ann. Oncol. 28, 136\u2013141 (2017).","journal-title":"Ann. Oncol."},{"key":"74_CR67","first-page":"456O","volume":"27","author":"F-C Bidard","year":"2016","unstructured":"Bidard, F.-C. et al. Circulating tumor DNA and circulating tumor cells as predictor of outcome in the PRODIGE14-ACCORD21-METHEP2 phase II trial. Ann. Oncol. 27, 456O (2016).","journal-title":"Ann. Oncol."},{"key":"74_CR68","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1158\/1078-0432.CCR-17-0232","volume":"23","author":"AR Thierry","year":"2017","unstructured":"Thierry, A. R. et al. Circulating DNA demonstrates convergent evolution and common resistance mechanisms during treatment of colorectal cancer. Clin. Cancer Res. 23, 4578\u20134591 (2017).","journal-title":"Clin. Cancer Res."},{"key":"74_CR69","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40425-014-0042-0","volume":"2","author":"EJ Lipson","year":"2014","unstructured":"Lipson, E. J. et al. Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J. Immunother. Cancer 2, 42 (2014).","journal-title":"J. Immunother. Cancer"},{"key":"74_CR70","doi-asserted-by":"crossref","first-page":"38056","DOI":"10.18632\/oncotarget.16935","volume":"8","author":"N Guibert","year":"2017","unstructured":"Guibert, N. et al. Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma. Oncotarget 8, 38056\u201338060 (2017).","journal-title":"Oncotarget"},{"key":"74_CR71","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/jamaoncol.2017.5332","volume":"4","author":"JH Lee","year":"2018","unstructured":"Lee, J. H. et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies. JAMA Oncol. 4, 717\u2013721 (2018).","journal-title":"JAMA Oncol."},{"key":"74_CR72","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1158\/1078-0432.CCR-17-0231","volume":"23","author":"GJ Weiss","year":"2017","unstructured":"Weiss, G. J. et al. Tumor cell-free DNA copy number instability predicts therapeutic response to immunotherapy. Clin. Cancer Res. 23, 5074\u20135081 (2017).","journal-title":"Clin. Cancer Res."},{"key":"74_CR73","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1158\/1078-0432.CCR-17-1341","volume":"24","author":"SB Goldberg","year":"2018","unstructured":"Goldberg, S. B. et al. Early assessment of lung cancer immunotherapy response via circulating tumor DNA. Clin. Cancer Res. 24, 1872\u20131880 (2018).","journal-title":"Clin. Cancer Res."},{"key":"74_CR74","doi-asserted-by":"crossref","first-page":"11538","DOI":"10.1200\/JCO.2017.35.15_suppl.11538","volume":"35","author":"M Kuziora","year":"2017","unstructured":"Kuziora, M. et al. Association of early reduction in circulating tumor DNA (ctDNA) with improved progression-free survival (PFS) and overall survival (OS) of patients (pts) with urothelial bladder cancer (UBC) treated with durvalumab (D). J. Clin. Oncol. 35, 11538\u201311538 (2017).","journal-title":"J. Clin. Oncol."},{"key":"74_CR75","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1158\/1538-7445.AM2017-582","volume":"77","author":"MA Kuziora","year":"2017","unstructured":"Kuziora, M. A., Higgs, B. W., Brohawn, P., Raja, R. & Ranade, K. Circulating tumor DNA (ctDNA) variant allele frequencies are reduced in responders to durvalumab and low baseline variant allele frequencies are associated with improved overall survival in NSCLC patients [abstract]. Cancer Res. 77, 582 (2017).","journal-title":"Cancer Res."},{"key":"74_CR76","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ejca.2017.09.004","volume":"86","author":"Y Iijima","year":"2017","unstructured":"Iijima, Y. et al. Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer. Eur. J. Cancer 86, 349\u2013357 (2017).","journal-title":"Eur. J. Cancer"},{"key":"74_CR77","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1200\/JCO.2017.35.15_suppl.7552","volume":"35","author":"S Dahiya","year":"2017","unstructured":"Dahiya, S. et al. Circulating tumor DNA assessment in patients with diffuse large B cell lymphoma following CAR-T therapy. J. Clin. Oncol. 35, 7552\u20137552 (2017).","journal-title":"J. Clin. Oncol."},{"key":"74_CR78","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1373\/clinchem.2013.203679","volume":"59","author":"SCY Yu","year":"2013","unstructured":"Yu, S. C. Y. et al. High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing. Clin. Chem. 59, 1228\u20131237 (2013).","journal-title":"Clin. Chem."},{"key":"74_CR79","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/pcmr.12503","volume":"29","author":"BY Kong","year":"2016","unstructured":"Kong, B. Y. et al. Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy. Pigment Cell. Melanoma Res. 29, 572\u2013577 (2016).","journal-title":"Pigment Cell. Melanoma Res."},{"key":"74_CR80","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature11219","volume":"486","author":"LA Diaz","year":"2012","unstructured":"Diaz, L. A. et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537\u2013540 (2012).","journal-title":"Nature"},{"key":"74_CR81","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.immuni.2017.02.001","volume":"46","author":"S George","year":"2017","unstructured":"George, S. et al. Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. Immunity 46, 197\u2013204 (2017).","journal-title":"Immunity"},{"key":"74_CR82","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng, W. et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 6, 202\u2013216 (2016).","journal-title":"Cancer Discov."},{"key":"74_CR83","doi-asserted-by":"crossref","first-page":"13587","DOI":"10.18632\/oncotarget.7277","volume":"7","author":"KC Strickland","year":"2016","unstructured":"Strickland, K. C. et al. Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer. Oncotarget 7, 13587\u201313598 (2016).","journal-title":"Oncotarget"},{"key":"74_CR84","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1158\/2326-6066.CIR-15-0024","volume":"3","author":"EM Allen Van","year":"2015","unstructured":"Van Allen, E. M. et al. Long-term benefit of PD-L1 blockade in lung cancer associated with JAK3 activation. Cancer Immunol. Res. 3, 855\u2013863 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"74_CR85","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","volume":"7","author":"DS Shin","year":"2017","unstructured":"Shin, D. S. et al. Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations. Cancer Discov. 7, 188\u2013201 (2017).","journal-title":"Cancer Discov."},{"key":"74_CR86","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N.\u00a0Engl. J. Med. 375, 819\u2013829 (2016).","journal-title":"N. Engl. J. Med."},{"key":"74_CR87","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature23477","volume":"548","author":"SJ Patel","year":"2017","unstructured":"Patel, S. J. et al. Identification of essential genes for cancer immunotherapy. Nature 548, 537\u2013542 (2017).","journal-title":"Nature"},{"key":"74_CR88","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.aan5951","volume":"359","author":"D Miao","year":"2018","unstructured":"Miao, D. et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 359, 801\u2013806 (2018).","journal-title":"Science"},{"key":"74_CR89","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/jnci\/djx118","volume":"109","author":"AW Wyatt","year":"2017","unstructured":"Wyatt, A. W. et al. Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer. J. Natl Cancer Inst. 109, 78\u201386 (2017).","journal-title":"J. Natl Cancer Inst."},{"key":"74_CR90","doi-asserted-by":"crossref","first-page":"101325","DOI":"10.18632\/oncotarget.20722","volume":"8","author":"M Ratajska","year":"2017","unstructured":"Ratajska, M. et al. Detection of BRCA1\/2mutations in\u00a0circulating tumor DNA from patients with ovarian cancer. Oncotarget 8, 101325\u2013101332 (2017).","journal-title":"Oncotarget"},{"key":"74_CR91","doi-asserted-by":"crossref","first-page":"40481","DOI":"10.18632\/oncotarget.9629","volume":"7","author":"W Liao","year":"2016","unstructured":"Liao, W. et al. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing. Oncotarget 7, 40481\u201340490 (2016).","journal-title":"Oncotarget"},{"key":"74_CR92","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","volume":"36","author":"SS Ramalingam","year":"2018","unstructured":"Ramalingam, S. S. et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J. Clin. Oncol. 36, 841\u2013849 (2018).","journal-title":"J. Clin. Oncol."},{"key":"74_CR93","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69\u201374 (2015).","journal-title":"Science"},{"key":"74_CR94","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/2326-6066.CIR-16-0019","volume":"5","author":"T Nathanson","year":"2017","unstructured":"Nathanson, T. et al. Somatic mutations and neoepitope homology in melanomas treated with CTLA-4 blockade. Cancer Immunol. Res. 5, 84\u201391 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"74_CR95","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463\u20131469 (2016).","journal-title":"Science"},{"key":"74_CR96","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","volume":"7","author":"V Anagnostou","year":"2017","unstructured":"Anagnostou, V. et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov. 7, 264\u2013276 (2017).","journal-title":"Cancer Discov."},{"key":"74_CR97","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/ng.3648","volume":"48","author":"P Ulz","year":"2016","unstructured":"Ulz, P. et al. Inferring expressed genes by whole-genome sequencing of plasma DNA. Nat. Genet. 48, 1273\u20131278 (2016).","journal-title":"Nat. Genet."},{"issue":"Suppl. 13","key":"74_CR98","volume":"16","author":"M Ivanov","year":"2015","unstructured":"Ivanov, M., Baranova, A., Butler, T., Spellman, P. & Mileyko, V. Non-random fragmentation patterns in circulating cell-free DNA reflect epigenetic regulation. BMC Genomics 16 (Suppl. 13), S1 (2015).","journal-title":"BMC Genomics"},{"key":"74_CR99","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fgene.2018.00006","volume":"9","author":"EC Maggi","year":"2018","unstructured":"Maggi, E. C. et al. Development of a method to implement whole-genome bisulfite sequencing of cfDNA from cancer patients and a mouse tumor model. Front. Genet. 9, 6 (2018).","journal-title":"Front. Genet."},{"key":"74_CR100","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-16-3556","volume":"77","author":"A Prat","year":"2017","unstructured":"Prat, A. et al. Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma. Cancer Res. 77, 3540\u20133550 (2017).","journal-title":"Cancer Res."},{"key":"74_CR101","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nm.3870","volume":"21","author":"G Siravegna","year":"2015","unstructured":"Siravegna, G. et al. Clonal evolution and resistance to\u00a0EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 21, 795\u2013801 (2015).","journal-title":"Nat. Med."},{"key":"74_CR102","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","volume":"36","author":"JD Merker","year":"2018","unstructured":"Merker, J. D. et al. Circulating tumor DNA analysis in patients with cancer: american society of clinical oncology and college of american pathologists joint review. J. Clin. Oncol. 36, 1631\u20131641 (2018).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41571-018-0074-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41571-018-0074-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41571-018-0074-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:27:03Z","timestamp":1684607223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-018-0074-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,26]]},"references-count":102,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["74"],"URL":"https:\/\/doi.org\/10.1038\/s41571-018-0074-3","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,26]]},"assertion":[{"value":"26 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.P., M.-H.S., and F.-C.B. have ongoing patent applications relating to circulating tumour DNA analysis. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}